Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTPPF: Neoadjuvant Pyrotinib + Trastuzumab + Palbociclib + Fulvestrant in Breast Cancer
NCT05076695Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Fudan University. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05076695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076695.